Viewing Study NCT06896760


Ignite Creation Date: 2025-12-25 @ 2:17 AM
Ignite Modification Date: 2025-12-27 @ 10:49 PM
Study NCT ID: NCT06896760
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-03-26
First Post: 2025-03-20
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Mass Balance Study of [14C]ABSK011
Sponsor: Abbisko Therapeutics Co, Ltd
Organization:

Study Overview

Official Title: A Mass Balance Study of [14C]ABSK011 in Healthy Adult Male Chinese Participants
Status: NOT_YET_RECRUITING
Status Verified Date: 2025-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study is a single-site, open-label, single-cohort, single-dose study to assess the absorption, metabolism, and excretion profile of \[14C\] ABSK011 in healthy adult male subjects. The study plans to enroll 6 to 8 healthy male subjects to ensure at least 6 evaluable subjects.
Detailed Description: Participants will be screened no more than 14 days before the dose (D-14 through D-3) and admitted to the clinical trial unit 2 days before the dose (D-2). Participants will receive a single oral administration of approximately 200 mg/120 µCi \[14C\]ABSK-011 suspension after a low-fat breakfast on day 1 morning.

Urine and stool samples will be collected from participants before and at specified intervals between 0 and 192 hours after taking the drug and blood samples will be collected at specified time points between 0 and 120 hours before and after taking the drug.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: